ibi3032
Small moleculeexperimental
Clinical trial activity
4 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
4
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Aug 27, 2025 (NCT07160400)
Timeline
2020s
- Jan 1, 2025
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
GLP1R agonist
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07170319 | Phase 1 | Oct 1, 2025 | Innovent Biologics (Suzhou) Co. Ltd. |
| NCT07120425 | Phase 1 | Sep 10, 2025 | Innovent Biologics (Suzhou) Co. Ltd. |
| NCT07134127 | Early Phase 1 (Phase 1) | Aug 29, 2025 | Innovent Biologics (Suzhou) Co. Ltd. |
| NCT07160400 | Phase 1 | Aug 27, 2025 | Innovent Biologics (Suzhou) Co. Ltd. |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Innovent Biologics (Suzhou) Co. Ltd. | For profit | 4 | 4 | 1 | 2025 |
1 organizations
Page 1 / 1